BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28494754)

  • 1. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.
    Tran DH; Wang J; Ha C; Ho W; Mattai SA; Oikonomopoulos A; Weiss G; Lacey P; Cheng M; Shieh C; Mussatto CC; Ho S; Hommes D; Koon HW
    BMC Gastroenterol; 2017 May; 17(1):63. PubMed ID: 28494754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High circulating elafin levels are associated with Crohn's disease-associated intestinal strictures.
    Wang J; Ortiz C; Fontenot L; Xie Y; Ho W; Mattai SA; Shih DQ; Koon HW
    PLoS One; 2020; 15(4):e0231796. PubMed ID: 32287314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum galectins as potential biomarkers of inflammatory bowel diseases.
    Yu TB; Dodd S; Yu LG; Subramanian S
    PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
    Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
    Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of fibrostenosing inflammatory bowel disease.
    Mak JWY; Ng SC
    J Dig Dis; 2020 Jun; 21(6):332-335. PubMed ID: 32105396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases.
    Schauber J; Rieger D; Weiler F; Wehkamp J; Eck M; Fellermann K; Scheppach W; Gallo RL; Stange EF
    Eur J Gastroenterol Hepatol; 2006 Jun; 18(6):615-21. PubMed ID: 16702850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
    Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
    J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
    Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
    Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
    Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease.
    Xu M; Cen M; Chen X; Chen H; Liu X; Cao Q
    Biomed Res Int; 2019; 2019():6517549. PubMed ID: 31950048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.
    Hosomi S; Yamagami H; Itani S; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    J Crohns Colitis; 2018 Jan; 12(1):87-95. PubMed ID: 28961693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
    Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
    World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
    de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
    J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.